Boston Scientific Pulse Field Ablation System Meets Clinical Endpoints For Persistent AF
Patients Able To Discontinue Use Of Anti-arrhythmic Drugs Following PFA Treatment
Boston Scientific's Farapulse Pulsed Field Ablation System achieved safety and effectiveness endpoints in the ADVANTAGE AF clinical trial for the treatment of persistent atrial fibrillation, supporting “the paradigm shift to pulse-field ablation,” said Vivek Reddy, director of electrophysiology at Mount Sinai Fuster Heart Hospital.
